Vaxart Faces Delisting Concerns
Ticker: VXRT · Form: 8-K · Filed: Jul 2, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: VXRT
TL;DR
Vaxart's on notice for potential delisting from Nasdaq.
AI Summary
Vaxart, Inc. filed an 8-K on July 2, 2025, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates a potential issue with meeting Nasdaq's continued listing requirements as of July 1, 2025. The company was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the stock being delisted from Nasdaq, impacting liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning that can lead to significant stock price declines and reduced trading activity.
Key Numbers
- July 1, 2025 — Date of earliest event (Date Vaxart potentially failed to meet listing standards)
- July 2, 2025 — Filing Date (Date the 8-K was filed with the SEC)
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Nasdaq (company) — Stock Exchange
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
FAQ
What specific listing rule or standard did Vaxart, Inc. fail to satisfy?
The filing does not specify the exact rule or standard that Vaxart, Inc. failed to satisfy, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
What is the exact date of the event triggering this notice?
The earliest event reported is July 1, 2025.
What actions, if any, is Vaxart, Inc. taking to address the delisting concern?
The provided text of the 8-K filing does not detail any specific actions Vaxart, Inc. is taking to address the delisting concern.
What is Vaxart, Inc.'s stock ticker symbol?
The filing does not explicitly state the stock ticker symbol, but the document name 'vxrt20250702_8k.htm' suggests it is VXRT.
When was Vaxart, Inc. previously known by other names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change date 20160413), Biota Pharmaceuticals, Inc. (name change date 20121113), and NABI BIOPHARMACEUTICALS (name change date 20100719).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Vaxart, Inc. (VXRT).